CHARLOTTE, NC–( EMWNews – April 7, 2008) – BurnsAdler Pharmaceuticals, Inc.

(“BurnsAdler”) announced today that Collatamp™ EG has received marketing

approval from ANVISA – National Agency for Surveillance in Brazil.

Collatamp™ EG is a fully resorbable Gentamicin-impregnated Collagen

Sponge, used as a surgical implant for local haemostasis of capillary,

parenchymatous and seeping hemorrhages in areas with a high risk of

infection. BurnsAdler will be co-marketing Collatamp™ EG with its local

partner Meizler Biopharma, S.A. (“Meizler”).

Bryan Somerville, Chief Operating Officer of BurnsAdler, remarked, “We are

very pleased to receive approval for Collatamp™ EG in Brazil and for the

opportunity to bring this advanced technology into a new market.

Collatamp™ EG is the only Gentamycin-impregnated Collagen Sponge in the

world, and allows medical providers to reduce patient costs and mean

duration of hospital stay. Through our strategic partnership with Meizler

and direct promotional efforts, we look forward to positive results in

Brazil.”

Avi Meizler, President of Meizler, remarked, “It is a great pleasure to

share with you the approval and very soon launching of Collatamp™ in

Brazil. We are truly confident that this very valuable product — within

the Brazilian market — will definitely contribute in the improvement of

the medical practices and, of course, better quality of life for the

patients. We are also looking forward to sharing with our partners,

BurnsAdler Pharmaceuticals, the success of Collatamp™ in the very near

future.”

About Collatamp™ EG

Collatamp™ EG is based on Innocoll Inc.’s proprietary collagen

CollaRx® (collagen sponge matrix) drug delivery technology. It is

approved in over 50 countries worldwide and is marketed under a variety of

other trade names in Europe, the Middle East, Africa and Asia. BurnsAdler

licensed the product for sale in various Latin American countries from

Innocoll Pharmaceuticals in August 2006. In 2007, EUSA Pharma Inc. acquired

all worldwide rights from Innocoll, with the exception of the U.S., and all

agreements with BurnsAdler were maintained.

About Meizler Biopharma, S.A.

Meizler is a Brazilian medical and hospital-focused company that has been

in existence for eighteen years. The company has held several international

partnerships with a variety of companies in Europe, the United States and

Asia. Meizler’s portfolio currently includes products in the following

categories: anesthetic, antipsychotic, antibiotics, biotechnology-vaccines,

cardiovascular, haemoderivaties and human reproduction hormones.

www.meizler.com.br

About BurnsAdler Pharmaceuticals, Inc.

BurnsAdler is a specialty pharmaceutical company that in-licenses and

promotes products in South America, Mexico, Canada, Puerto Rico and the

Caribbean. BurnsAdler’s portfolio currently includes products targeted for

the gastroenterology, cardiovascular, orthopedic, oncology, and critical

care markets.

For additional information about this news release contact Natalie Legra at

+1.704.552.8410 Ext. 232. For additional information about BurnsAdler,

please refer to the company’s website at www.burnsadler.com.